July 2023

Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.

There are currently no effective treatments for CIPN prevention.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Neither of the 2 current standards of care offers patients a cure.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Updated phase 3 trial data provide practice-changing findings.

These study results may inform clinical practice strategies this year and beyond.

The American Society of Clinical Oncology (ASCO) Annual Meeting includes updates from some of the most important clinical trials being conducted in the field of oncology.